Isovaleric acidemia, the genotype-phenotype question
IVD deficiency. Sweaty-feet odor, two historical phenotypes, and a common mild variant identified through expanded screening that often does not produce clinical disease. The genotype-phenotype question that has shaped IVA management for two decades.
Isovaleric acidemia was one of the first organic acid disorders to be characterized biochemically, in 1966, by Tanaka and colleagues. The clinical picture they described was the severe neonatal-onset form: a previously well newborn who in the first weeks of life develops vomiting, lethargy, severe metabolic acidosis with elevated anion gap, hyperammonemia, and a characteristic odor of sweaty feet from accumulated isovaleric acid. Without treatment the picture progressed to coma or death. Survivors had a chronic intermittent course with episodes triggered by illness or protein load.
After the introduction of tandem mass spectrometry to expanded newborn screening, the recognized clinical picture of IVA changed substantially. A common variant, c.932C>T (p.Ala282Val), was identified in screen-positive infants who, on follow-up, never developed clinical disease. The genotype-phenotype correlation question that this variant raised has shaped the clinical management of IVA in screened populations for two decades.
What IVA is
Isovaleric acidemia is an autosomal recessive organic acid disorder caused by deficiency of isovaleryl-CoA dehydrogenase (IVD), encoded by IVD on chromosome 15q14. IVD catalyzes the third step of leucine catabolism, converting isovaleryl-CoA to 3-methylcrotonyl-CoA. When IVD activity is reduced or absent, isovaleryl-CoA, isovaleric acid, 3-hydroxyisovaleric acid, isovalerylglycine, and isovalerylcarnitine accumulate. Free isovaleric acid produces the characteristic odor described as sweaty feet, and the smell is sometimes the first clinical clue at the bedside.
The historical clinical picture splits into two phenotypes. The acute neonatal form, with severe variants producing little or no IVD activity, presents in the first days to two weeks of life with the metabolic crisis described above. Without treatment, mortality is high. The chronic intermittent form, with variants producing residual activity, presents in older infants or children with episodes of vomiting, ketoacidosis, and lethargy triggered by infection or protein load, and is asymptomatic between episodes. Both phenotypes can occur in the same family and reflect variant-specific residual enzyme activity rather than separate genetic disorders.
The c.932C>T variant, which became apparent through newborn screening, is associated with substantial residual IVD activity. Most affected individuals carrying this variant in homozygous or compound heterozygous form, particularly in compound heterozygous form with another mild variant, never develop the metabolic crisis biology that defines classical IVA. Some carry residual biochemical abnormalities (mildly elevated isovalerylcarnitine on screen, low-level isovalerylglycine excretion) without clinical disease.
Reported live-birth incidence in expanded newborn screening programs runs roughly 1 in 50,000 to 1 in 250,000, with the lower numbers reflecting the inclusion of mild-variant cases that the pre-screening clinical-recognition era would not have identified.
Detection
Newborn screening uses tandem mass spectrometry on the dried blood spot to flag elevated isovalerylcarnitine, C5. The C5 marker also reflects 2-methylbutyrylcarnitine and pivaloylcarnitine, the latter produced when nursing mothers or infants receive certain antibiotics (pivampicillin and others). Second-tier testing distinguishes IVA from those alternative explanations through urine organic acid analysis (showing isovalerylglycine and 3-hydroxyisovaleric acid in IVA), plasma acylcarnitines, and IVD sequencing.
What management looks like
Standard of care for severe-variant IVA is a leucine-restricted diet using a leucine-free medical formula combined with measured natural protein, oral glycine supplementation, and oral L-carnitine supplementation. Glycine and carnitine each conjugate isovaleric acid in the body, forming isovalerylglycine and isovalerylcarnitine that the kidney excretes. The two conjugation pathways operate in parallel and are typically used together. A metabolic dietitian supervises calorie adequacy, growth, and protein sufficiency. Sick-day protocols use high-calorie low-protein intake during illness, and acute decompensations are managed with intravenous dextrose, correction of acidosis, fluid resuscitation, intravenous L-carnitine, and ammonia scavengers when hyperammonemia is present.
For mild-variant IVA, the management approach varies by center. Some centers treat all biochemically affected individuals with the full dietary and supplement regimen. Other centers stratify by biochemical severity and reserve full management for cases with elevated isovalerylglycine or persistent isovalerylcarnitine elevations, with sick-day protocols alone for mildly affected biochemistry. The variation reflects the underlying uncertainty about whether mild-variant biochemistry produces any clinical disease that intervention prevents.
The genotype-phenotype question is not unique to IVA. 3-methylcrotonyl-CoA carboxylase deficiency, short-chain acyl-CoA dehydrogenase deficiency, and several other expanded-screening conditions produce a similar split between cases that meet historical clinical recognition criteria and cases that exist only as biochemical abnormalities on screening. The infrastructure of long-term natural history studies that would resolve these questions exists for some of these conditions and not for others.
What this looks like for a family
A baby is born and the heel-prick is sent. On day 4, the state lab reports an elevated C5. On day 7, urine organic acids and IVD sequencing return biallelic IVD variants. The variant combination is c.932C>T in homozygous form. The metabolic team explains the genotype-phenotype context: the variant predicts a mild biochemical phenotype with low likelihood of clinical disease. Sick-day protocols are recommended. Whether the family pursues full dietary management or surveillance-only management depends on center practice and family preference.
A different baby with the same C5 elevation has IVD sequencing returning two severe variants. The metabolic team starts the leucine-restricted formula, glycine, and carnitine within the first weeks of life. Sick-day protocols are part of every febrile illness. The neonatal crisis that historically defined classical IVA does not occur.
That is what IVA care looks like in practice in the screening era. The screen identifies a population enriched for affected infants. The genotype refines the prediction. The management is calibrated to the specific variant combination. The cases that the pre-screening era never identified are now the larger fraction of the diagnosed population, and the field is still working out what to do with them.